CRSP
CRISPR Therapeutics AG
stock NASDAQ

Gene editing, starting to show success and on the forefront of medicine curing diseases. With this logic should demand high valuations, with some established leaders like CRSP, and many others competing. Yet as a whole, the sector has failed to impress the markets and has had a steep sell off from COVID highs. With many bagholders like myself. So I think market/popular narrative towards a sector has a lot to do with these valuations currently and can turn bearish when focus shifts

Xfinlink.com is pretty good, their data is point in time accurate (their entity resolution is actually somewhat on par with CRSP) & though they dont have real time yet you can probably workaround by connecting to ur broker

CRSP (gene editing), but will realistically need 5 years to 10x. absolutely undervalued, platform technology with 7 therapies in the clinic. regulators in favor of the technology and are actively trying to reduce time/cost to approval. already one approved drug, $2.3 billion in cash (they have no problem getting $600 million senior convertible notes in this macroeconomy, at a conversion rate 50% higher than current price and an interest rate significantly lower than inflation). big money has loaded up. over 90% is institutional, and it’s more than 20% shorted (probably some naked shorting too).

CRSP / Crispr

>Some countries have been outperforming the US for more than the past 50 years.
I know MSCI has index data going back to 1970, and CRSP has US index data going back to 1926. Do you have a source for a list of all individual countries that outperformed the US over the past 56 years (1970-2026) and past 100 years (1926-2026)?
I can find US data 1926-2026 on [testfol.io](http://testfol.io) with data from the Kenneth French data library: [https://mba.tuck.dartmouth.edu/pages/faculty/ken.french/data\_library.html](https://mba.tuck.dartmouth.edu/pages/faculty/ken.french/data_library.html)
* 1970-2026 (11.02% nominal CAGR): [https://testfol.io/?s=icq1M2UIs3r](https://testfol.io/?s=icq1M2UIs3r)
* 1926-2026 (10.32% nominal CAGR): [https://testfol.io/?s=dM2eqF8kBKN](https://testfol.io/?s=dM2eqF8kBKN)

Gene editing, starting to show success and on the forefront of medicine curing diseases. With this logic should demand high valuations, with some established leaders like CRSP, and many others competing. Yet as a whole, the sector has failed to impress the markets and has had a steep sell off from COVID highs. With many bagholders like myself. So I think market/popular narrative towards a sector has a lot to do with these valuations currently and can turn bearish when focus shifts

Xfinlink.com is pretty good, their data is point in time accurate (their entity resolution is actually somewhat on par with CRSP) & though they dont have real time yet you can probably workaround by connecting to ur broker

CRSP (gene editing), but will realistically need 5 years to 10x. absolutely undervalued, platform technology with 7 therapies in the clinic. regulators in favor of the technology and are actively trying to reduce time/cost to approval. already one approved drug, $2.3 billion in cash (they have no problem getting $600 million senior convertible notes in this macroeconomy, at a conversion rate 50% higher than current price and an interest rate significantly lower than inflation). big money has loaded up. over 90% is institutional, and it’s more than 20% shorted (probably some naked shorting too).

CRSP / Crispr

>Some countries have been outperforming the US for more than the past 50 years.
I know MSCI has index data going back to 1970, and CRSP has US index data going back to 1926. Do you have a source for a list of all individual countries that outperformed the US over the past 56 years (1970-2026) and past 100 years (1926-2026)?
I can find US data 1926-2026 on [testfol.io](http://testfol.io) with data from the Kenneth French data library: [https://mba.tuck.dartmouth.edu/pages/faculty/ken.french/data\_library.html](https://mba.tuck.dartmouth.edu/pages/faculty/ken.french/data_library.html)
* 1970-2026 (11.02% nominal CAGR): [https://testfol.io/?s=icq1M2UIs3r](https://testfol.io/?s=icq1M2UIs3r)
* 1926-2026 (10.32% nominal CAGR): [https://testfol.io/?s=dM2eqF8kBKN](https://testfol.io/?s=dM2eqF8kBKN)

NTLA will announce they have the HAE cure and the first in-vivo treatment which is actually commercially viable unlike the CRSP ex-vivo cure. If data is good, they will go from market cap of 1.6B back to 10B in the next year since the HAE market is substantial.